Institutional investors purchased a net $5.7 million shares of VICL during the quarter ended September 2017. This may signal that the smart money is gaining interest in this company as the 48.97% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ARMISTICE CAPITAL LLC Bought 300.0 Thousand shares of Vical Inc